Deal Watch: Dianthus Will Reach Public Markets Via Reverse Merger With Stalled-Out Magenta
After shutting down its trial for a leukemia conditioning agent due to a patient death, Magenta’s review of strategic alternatives concludes with a combination with complement inhibitor-focused Dianthus.
You may also be interested in...
Neuraxpharm Parts Company With API Subsidiary Inke
In light of its ongoing focus on European expansion and a desire to sharpen concentration on its central CNS business, Neuraxpharm has opted to divest its API subsidiary Inke to a private equity firm.
Janssen Gives Next-Gen CAR-Ts Another Shot After Fate Deal’s Collapse
A new collaboration with Cellular Biomedicine includes a CD19/CD20-directed bispecific CAR-T in Phase I development for B-cell non-Hodgkin lymphomas.
Sanofi Partners With Maze On Oral Pompe Drug
Deal Snapshot: Maze gets $150m up front in cash and equity in exchange for development and commercial rights to a GYS1 program for Pompe disease.